Pre-Open Stock Movers 01/25: (CKPT) (SDC) (AMRN) Higher; (AJRD) (GE) (NVDA) Lower (more...)

January 25, 2022 9:24 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Pre-Open Stock Movers:

Aerojet Rocketdyne (NYSE: AJRD) 13.8% LOWER; Earlier this month, Lockheed Martin (NYSE: LMT) and Aerojet Rocketdyne (NYSE: AJRD) agreed with the Federal Trade Commission (FTC) that we would not close the transaction before Jan. 27, 2022, to enable the parties to discuss the scope and nature of the merchant supply and firewall commitments previously offered by Lockheed Martin.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) 12.7% HIGHER; announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC).

SmileDirectClub, Inc. (Nasdaq: SDC) 6% HIGHER; announced a series of strategic actions to position the Company for improved business performance and future growth, including right-sizing its cost structure to better support core growth initiatives and allocating capital to countries with the greatest potential for near-term profitability.

Amarin Corp Plc (NASDAQ: AMRN) 5% HIGHER; Alex Denner's hedge fund Sarissa Capital Management LP disclosed a 6.06%, or 24,000,000 share, stake in the company.

General Electric (NYSE: GE) 5% LOWER; reported Q4 EPS of $0.92, $0.05 better than the analyst estimate of $0.87. Revenue for the quarter came in at $20.3 billion versus the consensus estimate of $21.48 billion.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) 4% LOWER; announced the presentation of results from the INTRIGUE Phase 3 study of QINLOCK (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib at the American Society of Clinical Oncology (ASCO) Plenary Series Session. The presentation, which follows the announcement in November 2021 of the top-line results, is titled INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and is available on the Companys website at www.deciphera.com/presentations-publications.

Nvidia (NASDAQ: NVDA) 4% LOWER; preparing to abandon its takeover of Arm after the tech giant barely made any progress in obtaining approval for the $40 billion acquisition, according to the report by Bloomberg

Checkpoint Software (NASDAQ: CHKP) 3.8% LOWER; Citi initiates coverage on with a Sell rating and a price target of $115.00.

Inter Parfums, Inc. (NASDAQ GS: IPAR) 3.2% HIGHER; announced that for the three months ended December 31, 2021, net sales rose to a record $210.8 million, a 15% increase from the fourth quarter of 2020, and 19% ahead of the fourth quarter of 2019. At comparable foreign currency exchange rates, consolidated fourth quarter net sales increased 15% from the fourth quarter of 2020 and 14% compared to the fourth quarter of 2019. Of note, the average dollar/euro exchange rates for the 2021, 2020 and 2019 fourth quarters were 1.14, 1.19 and 1.11, respectively.

lululemon athletica (NASDAQ: LULU) 2.4% LOWER; has filed for up to 5,203,012 share sale by the company's Canadian subsidiary.

SailPoint Technologies Holdings (NYSE: SAIL) 2% LOWER; Citi initiates coverage with a Sell rating and a price target of $35.00.

Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) 1.8% HIGHER; Announced preliminary financial results for the three and twelve months ended December 31, 2021. Revenue for the fourth quarter of 2021 is expected to be between $390 million and $395 million, versus the consensus of $386.75 million.

IBM (NYSE: IBM) 1.4% HIGHER; reported Q4 EPS of $3.35, $0.21 better than the analyst estimate of $3.14. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $15.98 billion.

Fastly Inc. (NYSE: FSLY) 1.3% LOWER; Citi initiates coverage with a Sell rating and a price target of $25.00.

3M Co. (NYSE: MMM) 1% HIGHER; reported Q4 EPS of $2.31, $0.29 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.6 billion versus the consensus estimate of $8.58 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Citi, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers